Cell | Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis 今天分享一篇来自哈佛医学院Dana-Farber癌症中心的Cell文章(2022.04) 潘荣清博士为该研究论文的第一作者,潘荣清和Anthony G. Letai教授为并列通讯作者。Anthony G. Letai教授的课题组主要从事癌细胞调亡功能失调的机制研究。 文章亮...
然而,在大多数试验中,基于NK细胞的免疫疗法的疗效仍然有限。因此非常需要增强NK细胞的杀伤力的策略。 在一项新的研究中,来自美国丹娜法伯癌症研究院和哈佛医学院的研究人员报告了一种潜在的新方法来提高NK细胞疗法的疗效。相关研究结果近期发表在Cell期刊上,论文标题为“Augmenting NK cell-based immunotherapy by ...
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immuno...
J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019). Article PubMed CAS Google Scholar Bi, J. & Tian, Z. NK cell dysfunction and checkpoint immunotherapy. Front. Immunol. 10, 1999 (2019). Article PubMed PubMed Central CAS...
Bria-IMT™ BriaCell Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. Upon achieving impressive survival and clinical benefit results in a Phase 2 stu...
F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–276 (2013). Article CAS PubMed Google Scholar Gajewski, T. F. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor ...
内容提示: ARTICLEIdentif i cation of CD318, TSPAN8 and CD66c astarget candidates for CAR T cell basedimmunotherapy of pancreatic adenocarcinomaDaniel Schäfer 1,2,3 , Stefan Tomiuk 1 , Laura N. Küster 1 , Wa’el Al Rawashdeh 1 , Janina Henze 1,2,3 ,German Tischler-Höhle 1 , ...
using VHH-based CAR-T cells against solid tumor cell lines in our lab [256,257]. As VHHs own advantages over scFvs for solid tumors [6], transferring VHH-based CAR into cells other than T cells that can penetrate deep tumors may provide an ideal immunotherapy platform against solid ...
and are associated with unfavorable prognosis and resistance to immunotherapy. Specific myeloid cell subpopulations, in particular LAMP3+ dendritic cells, appear to mediate the regulation of NK cell anti-tumor immunity. Our study...
NIH的Steven A. Rosenberg和Vid Leko合作探讨了不同肿瘤抗原类型的分子鉴定以及免疫治疗靶向的临床安全性和有效性,而且提出了提高抗原导向免疫疗法治疗转移性癌症的有效性和可行性,Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors。UCLA的Yvonne Y. Chen发表了综述文章Eng...